Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 22, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
- Share Sale: On November 16, 2005, the SmithKline Beecham Employee Benefit Trust sold 3,004 Ordinary shares on behalf of a participant in the GlaxoSmithKline Annual Investment Plan at a price of GBP 14.98 per share.
- Share Transfer: On November 21, 2005, the Trust notified the Company of the transfer of 10,380 Ordinary shares from the Trust to a participant in the Annual Investment Plan.
- Director Interest: Director Mr. J. Heslop holds an interest in the shares held within the Trust, consistent with other non-US employees and former employees who are potential beneficiaries of this discretionary fund.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly details compliance with Disclosure Rule 3.1 4R (1) (b).
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the scale of the reported transactions.
- Confirm the current market price of GlaxoSmithKline Ordinary Shares relative to the GBP 14.98 transaction price reported in November 2005.
- Review the full terms of the GlaxoSmithKline Annual Investment Plan to understand the mechanics of the share transfers and sales.